uniQure N.V. - Ordinary Shares – Cashflow (NASDAQ:QURE)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -134.83 M287.96 M-145.06 M-145.93 M-182.73 M-177.96 M -172.11 M Mittelzufluss aus Investitionstätigkeit -9.48 M-67.39 M-182.73 M-205.69 M162.97 M-321.62 M -243.16 M Zahlungsströme aus der Finanzierungstätigkeit 7.44 M94.86 M1.45 M362.72 M-59.49 M415.4 M 335.28 M Freier Cashflow -134.83 M287.96 M-145.06 M-145.93 M-182.73 M-178.4 M -172.56 M

uniQure N.V. - Ordinary Shares

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

QURE

Financials

uniQure N.V. - Ordinary Shares

Nachrichten

uniQure-Aktie springt um 20 % nach positiven FDA-Nachrichten von Wettbewerber Replimune

Biotech Investors Are Tuning Out the MAHA Chaos

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure strebt britische Zulassung für Huntington-Gentherapie AMT-130 an

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Führungswechsel bei der FDA: Mizuho stuft uniQure-Aktie auf "Outperform" hoch

Mizuho upgrades uniQure stock rating on FDA leadership change